Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Amgen
 More »

  • VC Firm Partners with Amgen, Novartis to Form 15+ Biotech Startups
    Atlas Venture is partnering with both Amgen-through the company's VC fund, Amgen Ventures-and Novartis in an effort to fuel translational research-based, early-stage startup ...
    5-17-2013
  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and ... for metastatic colorectal cancer, Amgen today said it has identified biomarkers ...
    5-16-2013
  • Biotechs Need to Walk the Walk on Drug Value
    ... Another precompetitive effort, DILI-sim Initiative, joins the Hamner Institutes for Health Sciences with 12 drug developers-Amgen, AZ, BMS, Eli Lilly, Gilead, Glaxo, Janssen, ...
    5-15-2013
  • Amgen Forms Joint Venture to Sell Vectibix in China
    Amgen and Zhejiang Beta Pharma said today they will form a joint venture to commercialize ... Ownership of the new venture, to be named Amgen-Beta Pharmaceuticals, will be split ...
    5-10-2013
  • Companion Diagnostics: 52 Pick-Up
    ... Financial terms not disclosed. Agilent Technologies (Dako) and Amgen Agreement announced February 20, 2012 Collaboration agreement to develop a diagnostic for "an Amgen cancer drug ...
    5-9-2013
  • OBT Joins Boehringer Ingelheim in Cancer Drug Collaboration
    with Seattle Genetics, Medarex (since acquired by Bristol-Myers Squibb), Amgen, Biosite (now Alere), and BioWa, as well as development alliances with Sanofi and Menarini. ...
    4-29-2013
  • GEN | Biolinks
    AltheRx Pharmaceuticals Altravax Amarin Ambit Biosciences Ambrx Ambry Genetics Amgen Amicus Therapeutics Amnis Amplimmune Amresco Amunix Amylin Pharmaceuticals Anaphore Anaspec ...
  • E&Y: Biotechs Must Walk the Walk on Drug Value
    ... Another precompetitive effort, DILI-sim Initiative, joins the Hamner Institutes for Health Sciences with 12 drug developers-Amgen, AZ, BMS, Eli Lilly, Gilead, Glaxo, Janssen, ...
    4-22-2013
  • Biosimilars: 10 Drugs to Watch
    ... chemotherapy. 2012 sales: $2.040 billion (Amgen) Patent status: Patent set to expire 2016 ... 2012 sales: $7.963 billion (includes $4.236 billion Amgen + $3.737 billion Pfizer). ...
    4-22-2013
  • CEO Perks
    Salary, $1.623 million Robert Bradway Amgen, president and CEO effective May 23, 2012 ... million ($2.704 million) Kevin W. Sharer Amgen, CEO through May 23, 2012; chairman ...
    4-12-2013
  • Pfizer, BIND Launch $210M+ Targeted Nanomedicine Collaboration
    ... Amgen said they would collaborate to develop an Accurin to treat a range of solid tumors, based on BIND's platform and Amgen's undisclosed proprietary kinase inhibitor. The Amgen ...
    4-2-2013
  • Amgen Melanoma Drug Meets Phase III Endpoint
    Amgen said its cancer drug candidate talimogene laherparepvec (TVEC) met its primary ... According to top-line results released yesterday by Amgen, TVEC led to complete or partial ...
    3-20-2013
  • People in the News
    Bell has more than 18 years of experience in running regulatory affairs at companies including Merck, Bristol-Myers Squibb, Aventis, and Amgen. Formerly, he was vp and global head ...
    3-15-2013
  • Biosimilars: Not So Far So Fast
    ... off its plans to copy arthritis treatment Enbrel after maker Amgen gained a new patent. In late 2011, Amgen reported that the patent for Enbrel had been extended by 17 years, ...
    3-15-2013
  • Top 20 Best-Selling Drugs of 2012
    ... #12. Neulasta (pegfilgrastim) Drug maker: Amgen 1 Indication(s): Neutropenia caused by ... 7 #3. Enbrel (etanercept) Drug maker: Amgen and Pfizer 8 Indication(s): Moderate to ...
    3-1-2013

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll